A 71-year-old metastatic HCC patient with RET amplification, high tumor mutation burden, and positive PD-L1 expression responded well to the combination of cabozantinib and nivolumab, achieving a PFS of over 25 months (103). Here, CD274 is linked to hepatocellular carcinoma.